Heron Therapeutics Inc


Stock Update (NASDAQ:HRTX): Heron Therapeutics Inc. Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced positive topline results from its Phase 2 study of the investigational agent HTX-011 in subjects undergoing abdominoplasty (Study …

Company Update (NASDAQ:HRTX): Heron Therapeutics Inc Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016

Heron Therapeutics Inc (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, …

Cantor Comments on Heron Therapeutics Inc (HRTX) As It Won FDA Approval

In a research report published Wednesday, Cantor analyst Chiara Russo reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX) with a price …

Brean Capital Weighs In On Heron Therapeutics Inc (HRTX) Following FDA Approval For Sustol

In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …

Cantor Chimes In On Heron Therapeutics Inc (HRTX) Following Phase 2 Clinical Success

Heron Therapeutics Inc (NASDAQ:HRTX) has found Phase 2 success with its lead product candidates for the prevention of post-operative pain, HTX-011 and HTX-011B. …

Company Update (NASDAQ:HRTX): Heron Therapeutics Inc Enters Into Loan Agreement for Up to $100 Million

Heron Therapeutics Inc (NASDAQ:HRTX), has entered into an agreement with Tang Capital Partners, LP whereby Tang Capital will lend the Company up to …

Stock Update (NASDAQ:HRTX): Heron Therapeutics Inc Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain

Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical …

Company Update (NASDAQ:HRTX): Heron Therapeutics Inc Announces Appointment of Christian Waage to Board of Directors

Heron Therapeutics Inc (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, …

Brean Capital Reiterates Buy on Heron Therapeutics Inc (HRTX) Following Positive FDA Update

In a research report issued Thuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts